Irina Belinsky, MD
Ophthalmic Plastic and Reconstructive Surgery · Austin, TXNPI 1073831087
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $4,592 with a category attached, or 65.3%. Amgen accounts for 79.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $3,176 and has fallen 89.7% since, to $327 in 2025.
Across 43 payments — averaging $106.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Alcon$384
- Biotissue Holdings Inc.$129
- Genentech USA, Inc.$127
- Johnson & Johnson Surgical Vision, Inc.$81
- GSK$67
- plus $145 from 5 others
What the payments were for
- Speaking & faculty fees$3,00065%
- Food & beverage$1,55734%
- Education$341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 26 | $3,659 |
| Alcon | 5 | $384 |
| Biotissue Holdings Inc. | 1 | $129 |
| Genentech USA, Inc. | 1 | $127 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $81 |
| GSK | 3 | $67 |
| ANI Pharmaceuticals, Inc. | 2 | $57 |
| Mimedx Group, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Dompe US, Inc. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$3,377
- Prokera$129
- AmnioGraft$129
- AcrySof IQ VIVITY IOL$129
- VABYSMO$127
- Clareon$118
- AcrySof IQ PanOptix$106
How this compares
$4,592 in reported general payments places this provider in the 75th percentile of 36 ophthalmic plastic and reconstructive surgery providers in Texas.
See all ophthalmic plastic and reconstructive surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 310 | $3,208 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 57 | $2,118 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 27 | $302 |
| Methylprednisolone | 20 | $103 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Austin
- Vikram DurairajAustin$379K
- Richard AllenAustin$32K
- Tanya KhanAustin$10K
- Sean BlaydonAustin$4K
- Kendall GoodyearAustin$3K
- Tanuj NakraAustin$2K
- Krista StewartAustin$2K
- John ShoreAustin$981
- David GayDripping Springs$93K
- Timothy McCulleyHouston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.